Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia

Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia

Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conventional d...

Full description

Bibliographic Details
Main Authors: Timothy Johanssen, Laura McVeigh, Sara Erridge, Geoffrey Higgins, Joelle Straehla, Margaret Frame, Tero Aittokallio, Neil O. Carragher, Daniel Ebner
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
glioblastoma stem cell
drug target combination
temozolamide
radiotherapy
hypoxia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1075559/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1075559/full

Similar Items